The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.

@article{Keohane2013TheRO,
  title={The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.},
  author={C. Keohane and R. Mesa and C. Harrison},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
  year={2013},
  pages={
          301-5
        }
}
  • C. Keohane, R. Mesa, C. Harrison
  • Published 2013
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
In 2005, the description of the JAK2V617F mutation for the first time provided a molecular key to enable more rapid diagnosis and target for novel therapeutics in the myeloproliferative neoplasms. In 2007, the first-in-class agent INC18424, ruxolitinib, JAKafi, or JAKAVI was first tested in patients with intermediate-risk 2 or high-risk myelofibrosis regardless of whether they possessed the JAK2V617F mutation. Patients treated with this agent had major reduction in splenomegaly as well as… Expand
6 Citations

References

SHOWING 1-10 OF 28 REFERENCES
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
...
1
2
3
...